Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.

MLA

Lee, Seung Hun, et al. “Hyperhomocysteinemia Due to Levodopa Treatment as a Risk Factor for Osteoporosis in Patients with Parkinson’s Disease.” Calcified Tissue International, vol. 86, no. 2, Feb. 2010, pp. 132–41. EBSCOhost, https://doi.org/10.1007/s00223-009-9327-6.

APA

Lee, S. H., Kim, M. J., Kim, B.-J., Kim, S. R., Chun, S., Kim, H.-K., Ryu, J. S., Kim, G. S., Lee, M. C., Chung, S. J., & Koh, J.-M. (2010). Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson’s disease. Calcified Tissue International, 86(2), 132–141. https://doi.org/10.1007/s00223-009-9327-6

Chicago

Lee, Seung Hun, Mi Jung Kim, Beom-Jun Kim, Sung Reul Kim, Sail Chun, Hong-Kyu Kim, Jin Sook Ryu, et al. 2010. “Hyperhomocysteinemia Due to Levodopa Treatment as a Risk Factor for Osteoporosis in Patients with Parkinson’s Disease.” Calcified Tissue International 86 (2): 132–41. doi:10.1007/s00223-009-9327-6.